SCHEMBL3989997

SCHEMBL3989997

CC(=N)N1CCC(c2cc(C(N)=O)on2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCD O00767 3/20 0.48
PDE2A O00408 1/20 0.37
SMYD3 Q9H7B4 4/20 0.37
SCD5 Q86SK9 3/20 0.36
PSMB8 P28062 1/20 0.36
PSMB9 P28065 1/20 0.36
PSMB5 P28074 1/20 0.36
PARP1 P09874 1/20 0.35
F10 P00742 1/20 0.33
RET P07949 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
CPN1 P15169 1/20 0.33
CPB2 Q96IY4 1/20 0.33
QDPR P09417 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3990440 0.89 SCD (0.50) SCDPDE2ASMYD3SCD5PSMB8
SCHEMBL3983823 0.82 SCD (0.55) SCDSCD5
SCHEMBL4149188 0.81 SCD (0.44) SCDPDE2ASMYD3PSMB8PSMB9
SCHEMBL3989771 0.80 SCD (0.44) SCDPDE2ASMYD3PSMB8PSMB9
SCHEMBL30489440 0.77 PSMB8 (0.50) SCDPDE2ASMYD3PSMB8PSMB9
SCHEMBL21317604 0.77 PSMB8 (0.50) SCDPDE2ASMYD3PSMB8PSMB9
SCHEMBL4947801 0.77 SCD (0.41) SCDPDE2ASMYD3SCD5PSMB8
SCHEMBL3981678 0.75 HRH4 (0.41) SCDSMYD3PSMB8PSMB9PSMB5
SCHEMBL3984724 0.73 DRD2 (0.51) SCDDRD2DRD4DRD3
SCHEMBL23930582 0.69 PSMB8 (0.51) PDE2ASMYD3PSMB8PSMB9PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP claimed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US claimed
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor TFPI, TFPI2, F12 SCD 3729/4885PDE2A 686/4885SMYD3 4252/4885
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 SCD 2658/4885PDE2A 607/4885SMYD3 4466/4885
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 SCD 2658/4885PDE2A 607/4885SMYD3 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.